BACKGROUND AND PURPOSE: Chronic cerebrospinal venous insufficiency (CCSVI) is a vascular condition characterized by anomalies of the main extracranial cerebrospinal venous routes that interfere with normal venous outflow. Research into CCSVI will determine its sensitivity and specificity for a diagnosis of MS, its prevalence in MS patients, and its clinical, MRI, and genetic correlates. Our aim was to investigate the prevalence and number of intra- and extraluminal structural and functional extracranial venous abnormalities by using DS and MRV, in patients with MS and HCs. MATERIALS AND METHODS: One hundred fifty patients with MS, 104 (69.3%) with RR and 46 (30.7%) with a progressive MS course, and 63 age- and sex-matched HCs were scanned with 3T MR imaging by using TOF and TRICKS sequences (only patients with MS). All subjects underwent DS examination for intra- and extraluminal structural and functional abnormalities of the IJVs. Absent/pinpoint IJV flow morphology on MRV was considered an abnormal finding. Prominence of collateral extracranial veins was assessed with MRV. RESULTS: Patients with MS had a significantly higher number of functional (P < .0001), total (P = .001), and intraluminal (P = .005) structural IJV DS abnormalities than HCs. There was a trend for more patients with MS with extraluminal IJV DS abnormalities (P = .023). No significant differences were found on the MRV IJV flow morphology scale between patients with MS and HCs. Patients with progressive MS showed more extraluminal IJV DS abnormalities (P = .01) and more MRV flow abnormalities on TOF (P = .006) and TRICKS (P = .01) than patients with nonprogressive MS. There was a trend for a higher number of collateral veins in patients with MS than in HCs (P = .016). CONCLUSIONS: DS is more sensitive than MRV in detecting intraluminal structural and functional venous abnormalities in patients with MS compared with HCs, whereas MRV is more sensitive in showing collaterals.
BACKGROUND AND PURPOSE:Chronic cerebrospinal venous insufficiency (CCSVI) is a vascular condition characterized by anomalies of the main extracranial cerebrospinal venous routes that interfere with normal venous outflow. Research into CCSVI will determine its sensitivity and specificity for a diagnosis of MS, its prevalence in MS patients, and its clinical, MRI, and genetic correlates. Our aim was to investigate the prevalence and number of intra- and extraluminal structural and functional extracranial venous abnormalities by using DS and MRV, in patients with MS and HCs. MATERIALS AND METHODS: One hundred fifty patients with MS, 104 (69.3%) with RR and 46 (30.7%) with a progressive MS course, and 63 age- and sex-matched HCs were scanned with 3T MR imaging by using TOF and TRICKS sequences (only patients with MS). All subjects underwent DS examination for intra- and extraluminal structural and functional abnormalities of the IJVs. Absent/pinpoint IJV flow morphology on MRV was considered an abnormal finding. Prominence of collateral extracranial veins was assessed with MRV. RESULTS:Patients with MS had a significantly higher number of functional (P < .0001), total (P = .001), and intraluminal (P = .005) structural IJV DS abnormalities than HCs. There was a trend for more patients with MS with extraluminal IJV DS abnormalities (P = .023). No significant differences were found on the MRV IJV flow morphology scale between patients with MS and HCs. Patients with progressive MS showed more extraluminal IJV DS abnormalities (P = .01) and more MRV flow abnormalities on TOF (P = .006) and TRICKS (P = .01) than patients with nonprogressive MS. There was a trend for a higher number of collateral veins in patients with MS than in HCs (P = .016). CONCLUSIONS:DS is more sensitive than MRV in detecting intraluminal structural and functional venous abnormalities in patients with MS compared with HCs, whereas MRV is more sensitive in showing collaterals.
Authors: M Filippi; M A Rocca; F Barkhof; R Bakshi; F Fazekas; O Khan; D Pelletier; A Rovira; J Simon Journal: AJNR Am J Neuroradiol Date: 2011-02-03 Impact factor: 3.825
Authors: Robert Zivadinov; Alexandra Lopez-Soriano; Bianca Weinstock-Guttman; Claudiu V Schirda; Christopher R Magnano; Kresimir Dolic; Cheryl L Kennedy; Christina L Brooks; Justine A Reuther; Kristin Hunt; Michelle Andrews; Michael G Dwyer; David W Hojnacki Journal: Radiology Date: 2010-12-21 Impact factor: 11.105
Authors: Mike P Wattjes; Bob W van Oosten; Wolter L de Graaf; Alexandra Seewann; Joseph C J Bot; René van den Berg; Bernard M J Uitdehaag; Chris H Polman; Frederik Barkhof Journal: J Neurol Neurosurg Psychiatry Date: 2010-10-27 Impact factor: 10.154
Authors: Omar Khan; Massimo Filippi; Mark S Freedman; Frederik Barkhof; Paula Dore-Duffy; Hans Lassmann; Bruce Trapp; Amit Bar-Or; Imad Zak; Marilyn J Siegel; Robert Lisak Journal: Ann Neurol Date: 2010-03 Impact factor: 10.422
Authors: P Zamboni; R Galeotti; E Menegatti; A M Malagoni; G Tacconi; S Dall'Ara; I Bartolomei; F Salvi Journal: J Neurol Neurosurg Psychiatry Date: 2008-12-05 Impact factor: 10.154
Authors: K Dolic; K Marr; V Valnarov; M G Dwyer; E Carl; J Hagemeier; C Kennedy; C Brooks; C Kilanowski; K Hunt; D Hojnacki; B Weinstock-Guttman; R Zivadinov Journal: Funct Neurol Date: 2011 Oct-Dec
Authors: M Tamizur Rahman; Sean K Sethi; David T Utriainen; J Joseph Hewett; E Mark Haacke Journal: Magn Reson Imaging Date: 2013-07-12 Impact factor: 2.546
Authors: Adnan H Siddiqui; Robert Zivadinov; Ralph H B Benedict; Yuval Karmon; Jihnhee Yu; Mary L Hartney; Karen L Marr; Vesela Valnarov; Cheryl L Kennedy; Murali Ramanathan; Deepa P Ramasamy; Kresimir Dolic; David W Hojnacki; Ellen Carl; Elad I Levy; L Nelson Hopkins; Bianca Weinstock-Guttman Journal: Neurology Date: 2014-06-27 Impact factor: 9.910
Authors: R Zivadinov; G Cutter; K Marr; M Ramanathan; R H B Benedict; N Bergsland; C Morgan; E Carl; D Hojnacki; E A Yeh; L Willis; M Cherneva; C Kennedy; M G Dwyer; B Weinstock-Guttman Journal: AJNR Am J Neuroradiol Date: 2012-05-10 Impact factor: 3.825
Authors: Claudiu I Diaconu; Susan M Staugaitis; Robert J Fox; Alexander Rae-Grant; Cynthia Schwanger; Jennifer M McBride Journal: Neurol Res Date: 2012-10 Impact factor: 2.448